An Expanded Access Program of SER-109 in patients with multiple recurrent Clostridium difficile infection (CDI)

Trial Profile

An Expanded Access Program of SER-109 in patients with multiple recurrent Clostridium difficile infection (CDI)

Recruiting
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 16 May 2016

At a glance

  • Drugs SER 109 (Primary)
  • Indications Clostridium infections
  • Focus Expanded access; Therapeutic Use
  • Most Recent Events

    • 16 May 2016 According to a Seres Therapeutics media release, company has initiated expanded access program at selected sites participating in the ongoing Phase 2 study
    • 05 May 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top